FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988909962> ?p ?o ?g. }

• W1988909962 endingPage "90" @default.
• W1988909962 startingPage "81" @default.
• W1988909962 abstract "To report the 8-year outcome of local dose escalation using high-dose-rate conformal brachytherapy combined with elective irradiation of the pelvic lymphatics for localized prostate cancer.One hundred forty-four consecutively treated men (1986-1992) were recorded prospectively. Twenty-nine (20.14%) patients had T1b-2a tumors, and 115 (79.86%) patients had T2b-3 tumors according to, respectively, American Joint Committee on Cancer/Union Internationale Contre le Cancer 1992. All patients had a negative nodal status, proven by CT or MRI. The mean initial PSA value was 25.61 ng/mL (Initial value for 41.66% of patients was <10 ng/mL, for 21.52% was 10-20 ng/mL, and for 32.63% was >20 ng/mL). The total dose applied by external beam radiotherapy was 50 Gy in the pelvis and 40 Gy in the prostate. The high-dose-rate brachytherapy was delivered in two fractions, which were incorporated into the external beam treatment (after 20-Gy and 40-Gy external beam radiotherapy dose). The dose per fraction was 15 Gy for the PTV1 (peripheral prostate zone) and 9 Gy for the PTV2 (entire prostatic gland). Any patient free of clinical or biochemical evidence of disease was termed bNED. Actuarial rates of outcome were calculated by Kaplan-Meier and compared using the log-rank. Cox regression models were used to establish prognostic factors of the various measures of outcome.The median follow-up was 8 years (range 60-171 months). The overall survival rate was 71.5%, and the disease-free survival rate was 82.6%. The bNED survival rate was 72.9%. Freedom from local recurrence for T3 stage was 91.3%, whereas for G3 lesions it was 88.23%. Freedom from distant recurrence for T3 stage was 82.6% and for G3 lesions 70.59%. Univariate survival analyses revealed that low stage (T1-2), low grade (G1-2), no hormonal therapy, initial PSA value less than 40 ng/mL, and PSA normalization <1.0 ng/mL after irradiation were associated with long survival. In multivariate analyses, initial PSA value, PSA kinetics after radiation therapy, and no adjuvant hormonal treatment were independent prognostic factors. Grade 3 late radiation toxicity (according to RTOG/EORTC scoring scheme) was 2.3% for the genitourinary system in terms of cystitis and 4.10% for the gastrointestinal system in terms of proctitis. Grades 4 and 5 genitourinary/gastrointestinal morbidity was not observed. A history of transurethral resection of the prostate with a median interval of less than 6 months from radiotherapy was associated with a high risk of genitourinary toxicity.The 8-year results confirm the feasibility and effectiveness of combined elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for cure of localized and especially high-risk prostate cancer." @default.
• W1988909962 created "2016-06-24" @default.
• W1988909962 creator A5006750230 @default.
• W1988909962 creator A5013235240 @default.
• W1988909962 creator A5019120462 @default.
• W1988909962 creator A5026011011 @default.
• W1988909962 creator A5029139642 @default.
• W1988909962 creator A5047853154 @default.
• W1988909962 creator A5048287664 @default.
• W1988909962 creator A5054741058 @default.
• W1988909962 creator A5081458044 @default.
• W1988909962 creator A5084096589 @default.
• W1988909962 date "2002-01-01" @default.
• W1988909962 modified "2023-10-16" @default.
• W1988909962 title "Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer" @default.
• W1988909962 cites W123162698 @default.
• W1988909962 cites W1660302799 @default.
• W1988909962 cites W1966226622 @default.
• W1988909962 cites W1979914233 @default.
• W1988909962 cites W1988094389 @default.
• W1988909962 cites W1994902640 @default.
• W1988909962 cites W2009301622 @default.
• W1988909962 cites W2016420175 @default.
• W1988909962 cites W2024787154 @default.
• W1988909962 cites W2026375990 @default.
• W1988909962 cites W2035093904 @default.
• W1988909962 cites W2040091965 @default.
• W1988909962 cites W2048516791 @default.
• W1988909962 cites W2053705002 @default.
• W1988909962 cites W2063266750 @default.
• W1988909962 cites W2069578101 @default.
• W1988909962 cites W2073097174 @default.
• W1988909962 cites W2075707807 @default.
• W1988909962 cites W2093485750 @default.
• W1988909962 cites W2137933052 @default.
• W1988909962 cites W2148214708 @default.
• W1988909962 cites W2159677793 @default.
• W1988909962 cites W2171367875 @default.
• W1988909962 cites W2314863838 @default.
• W1988909962 cites W2323868208 @default.
• W1988909962 cites W358109819 @default.
• W1988909962 cites W4231493653 @default.
• W1988909962 cites W4293241248 @default.
• W1988909962 doi "https://doi.org/10.1016/s0360-3016(01)01758-8" @default.
• W1988909962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11777625" @default.
• W1988909962 hasPublicationYear "2002" @default.
• W1988909962 type Work @default.
• W1988909962 sameAs 1988909962 @default.
• W1988909962 citedByCount "186" @default.
• W1988909962 countsByYear W19889099622012 @default.
• W1988909962 countsByYear W19889099622013 @default.
• W1988909962 countsByYear W19889099622014 @default.
• W1988909962 countsByYear W19889099622015 @default.
• W1988909962 countsByYear W19889099622016 @default.
• W1988909962 countsByYear W19889099622017 @default.
• W1988909962 countsByYear W19889099622018 @default.
• W1988909962 countsByYear W19889099622019 @default.
• W1988909962 countsByYear W19889099622020 @default.
• W1988909962 countsByYear W19889099622021 @default.
• W1988909962 countsByYear W19889099622023 @default.
• W1988909962 crossrefType "journal-article" @default.
• W1988909962 hasAuthorship W1988909962A5006750230 @default.
• W1988909962 hasAuthorship W1988909962A5013235240 @default.
• W1988909962 hasAuthorship W1988909962A5019120462 @default.
• W1988909962 hasAuthorship W1988909962A5026011011 @default.
• W1988909962 hasAuthorship W1988909962A5029139642 @default.
• W1988909962 hasAuthorship W1988909962A5047853154 @default.
• W1988909962 hasAuthorship W1988909962A5048287664 @default.
• W1988909962 hasAuthorship W1988909962A5054741058 @default.
• W1988909962 hasAuthorship W1988909962A5081458044 @default.
• W1988909962 hasAuthorship W1988909962A5084096589 @default.
• W1988909962 hasConcept C121608353 @default.
• W1988909962 hasConcept C126322002 @default.
• W1988909962 hasConcept C126838900 @default.
• W1988909962 hasConcept C126894567 @default.
• W1988909962 hasConcept C141071460 @default.
• W1988909962 hasConcept C2775908122 @default.
• W1988909962 hasConcept C2776235491 @default.
• W1988909962 hasConcept C2777416452 @default.
• W1988909962 hasConcept C2778357063 @default.
• W1988909962 hasConcept C2780192828 @default.
• W1988909962 hasConcept C2989005 @default.
• W1988909962 hasConcept C50382708 @default.
• W1988909962 hasConcept C509974204 @default.
• W1988909962 hasConcept C71924100 @default.
• W1988909962 hasConceptScore W1988909962C121608353 @default.
• W1988909962 hasConceptScore W1988909962C126322002 @default.
• W1988909962 hasConceptScore W1988909962C126838900 @default.
• W1988909962 hasConceptScore W1988909962C126894567 @default.
• W1988909962 hasConceptScore W1988909962C141071460 @default.
• W1988909962 hasConceptScore W1988909962C2775908122 @default.
• W1988909962 hasConceptScore W1988909962C2776235491 @default.
• W1988909962 hasConceptScore W1988909962C2777416452 @default.
• W1988909962 hasConceptScore W1988909962C2778357063 @default.
• W1988909962 hasConceptScore W1988909962C2780192828 @default.
• W1988909962 hasConceptScore W1988909962C2989005 @default.
• W1988909962 hasConceptScore W1988909962C50382708 @default.
• W1988909962 hasConceptScore W1988909962C509974204 @default.

• next